Brind.
From Amgen Repatha Trial Shows Cost-Effectiveness Below Industry Benchmark

How could the positive VESALIUS-CV trial results affect Mass General Brigham's standing?

Already happening What happens if… A possibility worth considering, not a forecast.

Mass General Brigham benefits from positive Amgen trial results The announcement of the VESALIUS-CV trial results, which showed Amgen's Repatha drug was cost-effective and significantly reduced cardiovascular risk, enhances the clinical reputation of Mass General Brigham. The trial was led by the Duke Clinical Research Institute in collaboration with the TIMI Study Group, which included Mass General Brigham. The results showed Repatha cut the combined risk of coronary heart disease death, heart attack, or ischemic stroke by 25% over a median of about 4.6 years. Furthermore, the health economic analysis found the drug was cost-effective for high-risk adults, coming in about 36% below the $120,000 per QALY benchmark set by the AHA and ACC.

Reported by 1 independent outlet Written Wednesday
Effect
Mild positive
How direct
Stated in the reporting
When
Right away
The story
No new developments lately

How it reaches Mass General Brigham

Reported by news outlets

Tap any step to see the evidence behind it.

The facts so far

As reported. Each one links to where it comes from.

  • The trial was led by the Duke Clinical Research Institute in collaboration with the TIMI Study Group at Mass General Brigham and Harvard.medicaldaily.com
  • Repatha cut the combined risk of coronary heart disease death, heart attack or ischemic stroke by 25% over a median of about 4.6 years.medicaldaily.com
  • The drug was found to be about 36% below a benchmark used by the American College of Cardiology and American Heart Association.medicaldaily.com
  • The 2025 AHA and ACC cost and value statement sets $120,000 per QALY as that threshold.medicaldaily.com

Why it matters

For Mass General Brigham, participation in high-profile, successful clinical trials like VESALIUS-CV reinforces its standing as a leader in cardiovascular research. Positive results, especially those demonstrating both clinical efficacy and cost-effectiveness, are crucial for attracting top medical talent, securing research funding, and maintaining its reputation among patients and peers.

This outcome is part of a broader trend where major academic medical centers collaborate with pharmaceutical companies and research institutes to drive medical innovation. The collaboration between Duke, Harvard, and Mass General Brigham highlights the power of large-scale, multi-institutional studies in establishing new standards of care and demonstrating the value of new treatments.

What we don't know yet

  • Will the full analysis of the VESALIUS-CV trial appear in a peer-reviewed journal?
  • How will the cost-effectiveness finding influence insurance coverage rules for Repatha?

What would change this answer

The full analysis is published in a peer-reviewed journal.The positive impact on Mass General Brigham's reputation will become more robust and academically validated.
Regulatory bodies change their willingness-to-pay thresholds for QALYs.The perceived value of the research conducted by the collaborating institutions could change significantly.

Who else could feel it

Other possible ripples from the same event.

Reporting

Keep going

The full eventAmgen Repatha Trial Shows Cost-Effectiveness Below Industry Benchmark Everything aboutMass General Brigham

Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.